Patient Voice

1417 Diet Patterns and Kidney Disease
   Michael J. Lennon
   See related editorial and article on pages 1419 and 1441, respectively.

Editorials

1419 Can Dietary Patterns Modify Risk for CKD?
   Emily A. Hu and Casey M. Rebholz
   See related Patient Voice and article on pages 1417 and 1441, respectively.

1421 Biomarkers to Predict Progression in IgA Nephropathy
   Chee Kay Cheung and Jonathan Barratt
   See related article on page 1458.

1424 Dietary Phosphorus and FGF23: Is More Restriction Better?
   Kathleen M. Hill Gallant
   See related article on page 1475.

1427 Is Hypertension Following Donor Nephrectomy Cause For Elevated Living Donor Kidney Function Concern?
   William S. Asch
   See related article on page 1493.

1430 Persistent Disparities in Preemptive Kidney Transplantation
   Tanjala S. Purnell and Deidra C. Crews
   See related article on page 1500.

Original Articles

Acute Kidney Injury and ICU Nephrology

1432 Kidney Support in Children using an Ultrafiltration Device: A Multicenter, Retrospective Study
   Shina Menon, John Broderick, Raj Munshi, Lynn Dill, Bradley DePaoli, Sahar Fathallah-Shaykh, Donna Claes, Stuart L. Goldstein, and David J. Askenazi

Chronic Kidney Disease

1441 Healthy Dietary Patterns and Incidence of CKD: A Meta-Analysis of Cohort Studies
   Katrina E. Bach, Jaimon T. Kelly, Suetonia C. Palmer, Saman Khalesi, Giovanni F. M. Strippoli, and Katrina L. Campbell
   See related Patient Voice and editorial on pages 1417 and 1419, respectively.

Glomerular and Tubulointerstitial Diseases

1450 Incidence of ESKD and Mortality among Children with Congenital Heart Disease after Cardiac Surgery
   Chirag R. Parikh, Jason H. Greenberg, Eric McArthur, Heather Thiessen-Philbrook, Allen D. Everett, Ron Wald, Michael Zappitelli, Rahul Chanchlani, and Amit X. Garg

1458 Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy
   Pei Chen, Guizhen Yu, Xue Zhang, Xinfang Xie, Jinwei Wang, Sufang Shi, Lijun Liu, Jicheng Lv, and Hong Zhang
   See related editorial on page 1421.
Maintenance Dialysis

1466 Peritoneal Dialysis Patient Outcomes under the Medicare Expanded Dialysis Prospective Payment System
Eric W. Young, Alissa Kapke, Zhechen Ding, Regina Baker, Jeffrey Pearson, Chad Cogan, Purna Mukhopadhyay, and Marc N. Turenne

1475 Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial
Wan-Chuan Tsai, Hon-Yen Wu, Yu-Sen Peng, Shih-Ping Hsu, Yen-Ling Chiu, Ju-Yeh Yang, Hung-Yuan Chen, Mei-Fen Pai, Wan-Yu Lin, Kuan-Yu Hung, Fang-Yeh Chu, Shu-Min Tsai, and Kuo-Liong Chien
See related editorial on page 1424.

Transplantation

1484 Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand
Samuel Chan, Elaine M. Pascoe, Philip A. Clayton, Stephen P. McDonald, Wai H. Lim, Matthew P. Sypek, Suetonia C. Palmer, Nicole M. Isbel, Ross S. Francis, Scott B. Campbell, Carmel M. Hawley, and David W. Johnson

1493 Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors
Courtenay M. Holscher, Christine E. Haugen, Kyle R. Jackson, Jacqueline M. Garonzik Wang, Madeleine M. Waldram, Sunjae Bae, Jayme E. Locke, Rhiannon D. Reed, Krista L. Lentine, Gaurav Gupta, Matthew R. Weir, John J. Friedewald, Jennifer Verbesey, Matthew Cooper, Dorry L. Segev, and Allan B. Massie
See related editorial on page 1427.

1500 Trends in Disparities in Preemptive Kidney Transplantation in the United States
Kristen L. King, Syed Ali Husain, Zhezhen Jin, Corey Brennan, and Sumit Mohan
See related editorial on page 1430.

1512 Circulating Advanced Glycation Endproducts and Long-Term Risk of Cardiovascular Mortality in Kidney Transplant Recipients

Research Letter

1521 The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial

Erratum

1524 Correction

Kidney Case Conference: How I Treat

1525 Vaccinating the Patient with ESKD
Sana F. Khan and Brendan T. Bowman

1528 Intravenous Iron Use in the Care of Patients with Kidney Disease
Iain C. Macdougall

Perspectives

1531 Real World Data and Evidence: Support for Drug Approval: Applications to Kidney Diseases
Aliza M. Thompson and Mary Ross Southworth

1533 Post-PIVOTAL Iron Dosing with Maintenance Hemodialysis
David Collister and Navdeep Tangri
On the Cover

What’s the diagnosis?
A 41-year-old male with type 2 diabetes mellitus taking dapagliflozin, one of sodium-glucose cotransporter-2 (SGLT2) inhibitors, 5 mg daily, was admitted to our hospital, with oliguric acute kidney injury. He reported no history of being exposed to IV contrast or other agents. Ultrasonography scans revealed no evidence of urinary tract obstruction, heart failure, or cirrhosis. Laboratory examination showed blood glucose of 74 mg/dL, hemoglobin A1c of 6.1 %, and serum creatinine of 3.0 mg/dL (baseline 1.1 mg/dL). Urinalysis was positive for glucose (+4) with osmolality of 836 mOsm/kg, and negative for protein, occult blood, crystals, or sediment abnormalities.

A histological preparation of kidney revealed focal isometric vacuolization in the proximal tubules (Figure 1) and pale periodic acid-Schiff (PAS)-positive glycogen accumulation within the cytoplasm of epithelial cells (Figure 2). Electron microscopy showed cytoplasmic vacuoles in the proximal tubules with preserved brush borders (Figure 3). A diagnosis of osmotic nephropathy, most likely due to dapagliflozin, was made. His physical status and serum creatinine level returned to normal after normal saline infusion and dapagliflozin discontinuation.

Osmotic nephropathy describes structural changes with vacuolization and swelling of the proximal tubules that obstruct urine flow, resulting in oliguric acute kidney injury. The known agents that cause osmotic nephropathy, include mannitol, contrast media and intravenous immunoglobulin. The similar lesion was first described in patients with poorly controlled diabetes or diabetic ketoacidosis in the late 1800s. However, it has been rarely seen for nearly a century, after the advent of insulin therapy and subsequent glucose lowering agents. Although it is premature to conclude that SGLT2 inhibitors caused osmotic nephropathy because of underlying diabetes and being based on a single case, and therefore needs further evaluation, this lesion could be associated with SGLT2 inhibitors, since these agents particularly increase the amount of urinary glucose, even on the condition of euglycemia, resulting in severe hyperglycosuria, that imposes a similar situation with the morphogenesis of osmotic nephropathy.

(Images and text were provided by Masayuki Yamanouchi, MD, MPH, Shun Watanabe, MD, Junichi Hoshino, MD, Yoshifumi Ubara, MD, Toranomon Hospital, Tokyo, Japan: Yutaka Yamaguchi, MD, Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan: and Kenichi Ohashi, MD, Department of Pathology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan)